Bing-Neel Syndrome Treatment Regimens
| Frontline treatment regimen | Number (n = 44) |
| Rituximab-cytarabine-MTX | 16 (36.4%) |
| MATRix (MTX-cytarabine-thiotepa-rituximab) | 15 (34.1%) |
| R-IDARAM (rituximab-MTX-cytarabine-idarubicin) | 5 (11.4%) |
| R-ESHAP/MTX (rituximab-etoposide-methylprednisolone-cytarabine-cisplatin) | 1 (2.3%) |
| Zanubrutinib | 4 |
| Ibrutinib | 1 |
| Intrathecal MTX | 1 |
| Intrathecal MTX/cytarabine/hydrocortisone | 1 |
| +BCNU/thiotepa ASCT consolidation | 3 |
| +BTKi consolidation | 15 |
| Second-line treatment regimen | n = 23/46 (50%) |
| Ibrutinib | 15 (65.2%) |
| Zanubrutinib | 6 (26.1%) |
| R-bendamustine | 1 (4.3%) |
| R-cladribine | 1 (4.3%) |
| Third-line treatment regimens | n = 3/46 (6.5%) |
| MATRix + ASCT | 1 |
| R-ICE (rituximab-ifosfamide-carboplatin-etoposide) + ASCT | 1 |
| R-bendamustine | 1 |
| Frontline treatment regimen | Number (n = 44) |
| Rituximab-cytarabine-MTX | 16 (36.4%) |
| MATRix (MTX-cytarabine-thiotepa-rituximab) | 15 (34.1%) |
| R-IDARAM (rituximab-MTX-cytarabine-idarubicin) | 5 (11.4%) |
| R-ESHAP/MTX (rituximab-etoposide-methylprednisolone-cytarabine-cisplatin) | 1 (2.3%) |
| Zanubrutinib | 4 |
| Ibrutinib | 1 |
| Intrathecal MTX | 1 |
| Intrathecal MTX/cytarabine/hydrocortisone | 1 |
| +BCNU/thiotepa ASCT consolidation | 3 |
| +BTKi consolidation | 15 |
| Second-line treatment regimen | n = 23/46 (50%) |
| Ibrutinib | 15 (65.2%) |
| Zanubrutinib | 6 (26.1%) |
| R-bendamustine | 1 (4.3%) |
| R-cladribine | 1 (4.3%) |
| Third-line treatment regimens | n = 3/46 (6.5%) |
| MATRix + ASCT | 1 |
| R-ICE (rituximab-ifosfamide-carboplatin-etoposide) + ASCT | 1 |
| R-bendamustine | 1 |
ASCT, autologous stem cell transplant; BCNU, carmustine; MTX, methotrexate.